New generation of dendritic cell vaccines

Dendritic cell-based vaccines

Dendritic cell (DC)-based anticancer vaccines have yielded disappointing results in a multitude of clinical trials. New data suggest that the clinical efficacy of DC-based vaccines may be dependent on the paracrine production of interleukin-12 in the course of antigen presentation and the consequent development of therapeutic Type 1 CD8+ T-cell immunity.

Dendritic cell vaccines Paul

1. Abstract 2. Introduction 3. Preparation of dendritic cells 3.1. Sources of dendritic cells 3.2. Dendritic cell mobilization strategies 3.3. Dendritic cell culture conditions 3.4. Methods of loading dendritic cells with tumor antigens 3.5. Dendritic cell maturation 3.6. The role of helper antigens 3.7. cryopreservation of dendritic cells 4. Administration of dendritic cell vaccines 4.1. Route...

Dendritic Cell-Targeted Vaccines

Despite significant effort, the development of effective vaccines inducing strong and durable T-cell responses against intracellular pathogens and cancer cells has remained a challenge. The initiation of effector CD8(+) T-cell responses requires the presentation of peptides derived from internalized antigen on class I major histocompatibility complex molecules by dendritic cells (DCs) in a proc...

Development of new African horsesickness cell culture killed vaccines

Peptide and dendritic cell vaccines.

There has been a rush to convert discovery of new melanoma antigens into cancer vaccines for the therapy of melanoma. The result has been disappointing from a clinical standpoint. The premise behind rapid pursuit of peptide vaccines for melanoma therapy was that the spontaneous tumor-associated immune response was too weak to be effective. However, it is increasingly clear that the host-tumor r...